Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2022 · 10-Q
Revenue$1.31K$1.31K−83.8% vs Q3 2021 Net Income-$2.03M-$2.03MN/M vs Q3 2021 EPS Diluted-$0.01-$0.01N/M vs Q3 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$321,225N/M Free Cash Flowderived-$323,935— Margins · derivedGross margin100.0%±0.0 pt vs Q3 2021
Operating margin-100298.3%−59958.0 pt vs Q3 2021
Net margin-154836.1%−114333.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end